These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 5567811)

  • 1. The metabolism of L-3-O-methyldopa, a precursor of dopa in man.
    Kuruma I; Bartholini G; Tissot R; Pletscher A
    Clin Pharmacol Ther; 1971; 12(4):678-82. PubMed ID: 5567811
    [No Abstract]   [Full Text] [Related]  

  • 2. 3-O-methyldopa, a new precursor of dopamine.
    Bartholini G; Kuruma I; Pletscher A
    Nature; 1971 Apr; 230(5295):533-4. PubMed ID: 4927759
    [No Abstract]   [Full Text] [Related]  

  • 3. The metabolic pathways of L-3-O-methyldopa.
    Bartholini G; Kuruma I; Pletscher A
    J Pharmacol Exp Ther; 1972 Oct; 183(1):65-72. PubMed ID: 5080035
    [No Abstract]   [Full Text] [Related]  

  • 4. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 5. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy.
    Sharpless NS; Tyce GM; Muenter MD; Dinapoli RP
    Clin Pharmacol Ther; 1974 Nov; 16(5 Part 1):770-81. PubMed ID: 4426145
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug-induced changes of extracerebral dopa metabolism in man.
    Tissot R; Bartholini G; Pletscher A
    Arch Neurol; 1969 Feb; 20(2):187-90. PubMed ID: 5767016
    [No Abstract]   [Full Text] [Related]  

  • 8. Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.
    Rivera-Calimlim L
    Br J Pharmacol; 1974 Feb; 50(2):259-63. PubMed ID: 4425764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of peripheral aromatic L-amino acids decarboxylase inhibitor on L-(2- 14 C)-3,4-dihydroxyphenylalanine metabolism in man.
    Messiha FS; Hsu TH; Bianchine JR
    Biochem Pharmacol; 1972 Aug; 21(15):2144-7. PubMed ID: 4645885
    [No Abstract]   [Full Text] [Related]  

  • 10. Demethylation of L-3-methoxytyrosine in vivo.
    Bartholini G; Pletscher A
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 274(4):404-9. PubMed ID: 4263632
    [No Abstract]   [Full Text] [Related]  

  • 11. The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects.
    Au WY; Dring LG; Grahame-Smith DG; Isaac P; Williams RT
    Biochem J; 1972 Aug; 129(1):1-10. PubMed ID: 4646774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of DOPA in rat stomach following ingestion of cereals.
    Hoeldtke RD; Wurtman RJ
    Metabolism; 1974 Jan; 23(1):25-31. PubMed ID: 4808509
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinsonism treated with 3-O-methyldopa.
    Calne DB; Reid JL; Vakil SD
    Clin Pharmacol Ther; 1973; 14(3):386-9. PubMed ID: 4698566
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 17. 3-O-methyl metabolites of catecholamines: automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa.
    Prasad AL; Fahn S
    Biochem Med; 1974 Feb; 9(2):136-47. PubMed ID: 4822034
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.
    Pletscher A; Bartholini G; Tissot R
    Brain Res; 1967 Feb; 4(1):106-9. PubMed ID: 6029941
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
    Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.